Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewswire
| 1733 Stock | TWD 28.50 0.15 0.53% |
Slightly above 53% of Apex Biotechnology's investor base is interested to short. The analysis of current outlook of investing in Apex Biotechnology Corp suggests that many traders are impartial regarding Apex Biotechnology's prospects. Apex Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Apex Biotechnology's earnings reports, geopolitical events, and overall market trends.
Apex Biotechnology stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Apex daily returns and investor perception about the current price of Apex Biotechnology Corp as well as its diversification or hedging effects on your existing portfolios.
Apex |
Cogent Biosciences Reports First Quarter 2024 Financial Results GlobeNewswire
Read at news.google.com
 |
Apex Biotechnology Fundamental Analysis
We analyze Apex Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Apex Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Apex Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Apex Biotechnology is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Apex Biotechnology Corp Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Apex Biotechnology stock to make a market-neutral strategy. Peer analysis of Apex Biotechnology could also be used in its relative valuation, which is a method of valuing Apex Biotechnology by comparing valuation metrics with similar companies.
Peers
Apex Biotechnology Related Equities
| 1723 | China Steel | 1.46 | ||||
| 1720 | Standard Chemical | 1.26 | ||||
| 1707 | Grape King | 0.65 | ||||
| 1734 | Sinphar Pharmaceutical | 0.16 |
Additional Tools for Apex Stock Analysis
When running Apex Biotechnology's price analysis, check to measure Apex Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apex Biotechnology is operating at the current time. Most of Apex Biotechnology's value examination focuses on studying past and present price action to predict the probability of Apex Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apex Biotechnology's price. Additionally, you may evaluate how the addition of Apex Biotechnology to your portfolios can decrease your overall portfolio volatility.